Literature DB >> 17507467

Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.

Wei Huang1, Susan H Eshleman, Jonathan Toma, Signe Fransen, Eric Stawiski, Ellen E Paxinos, Jeannette M Whitcomb, Alicia M Young, Deborah Donnell, Francis Mmiro, Philippa Musoke, Laura A Guay, J Brooks Jackson, Neil T Parkin, Christos J Petropoulos.   

Abstract

In human immunodeficiency virus type 1 (HIV-1) subtype B, CXCR4 coreceptor use ranges from approximately 20% in early infection to approximately 50% in advanced disease. Coreceptor use by non-subtype B HIV is less well characterized. We studied coreceptor tropism of subtype A and D HIV-1 collected from 68 pregnant, antiretroviral drug-naive Ugandan women (HIVNET 012 trial). None of 33 subtype A or 10 A/D-recombinant viruses used the CXCR4 coreceptor. In contrast, nine (36%) of 25 subtype D viruses used both CXCR4 and CCR5 coreceptors. Clonal analyses of the nine subtype D samples with dual or mixed tropism revealed heterogeneous viral populations comprised of X4-, R5-, and dual-tropic HIV-1 variants. In five of the six samples with dual-tropic strains, V3 loop sequences of dual-tropic clones were identical to those of cocirculating R5-tropic clones, indicating the presence of CXCR4 tropism determinants outside of the V3 loop. These dual-tropic variants with R5-tropic-like V3 loops, which we designated "dual-R," use CCR5 much more efficiently than CXCR4, in contrast to dual-tropic clones with X4-tropic-like V3 loops ("dual-X"). These observations have implications for pathogenesis and treatment of subtype D-infected individuals, for the association between V3 sequence and coreceptor tropism phenotype, and for understanding potential mechanisms of evolution from exclusive CCR5 use to efficient CXCR4 use by subtype D HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507467      PMCID: PMC1951291          DOI: 10.1128/JVI.00218-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 3.  HIV co-receptor inhibitors as novel class of anti-HIV drugs.

Authors:  Dominique Schols
Journal:  Antiviral Res       Date:  2006-05-06       Impact factor: 5.970

4.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1.

Authors:  C Tscherning-Casper; D Vödrös; E Menu; K Aperia; R Fredriksson; G Dolcini; G Chaouat; F Barré-Sinoussi; J Albert; E M Fenyö
Journal:  J Acquir Immune Defic Syndr       Date:  2000-05-01       Impact factor: 3.731

7.  HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

Authors:  Tom Melby; Michael Despirito; Ralph Demasi; Gabrielle Heilek-Snyder; Michael L Greenberg; Neil Graham
Journal:  J Infect Dis       Date:  2006-06-02       Impact factor: 5.226

8.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Authors:  Timothy J Wilkin; Zhaohui Su; Daniel R Kuritzkes; Michael Hughes; Charles Flexner; Robert Gross; Eoin Coakley; Wayne Greaves; Catherine Godfrey; Paul R Skolnik; Joseph Timpone; Benigno Rodriguez; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2007-01-17       Impact factor: 9.079

9.  HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.

Authors:  Jared M Baeten; Bhavna Chohan; Ludo Lavreys; Vrasha Chohan; R Scott McClelland; Laura Certain; Kishorchandra Mandaliya; Walter Jaoko; Julie Overbaugh
Journal:  J Infect Dis       Date:  2007-03-02       Impact factor: 5.226

10.  CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site.

Authors:  Peter Clevestig; Lotta Pramanik; Thomas Leitner; Anneka Ehrnst
Journal:  J Gen Virol       Date:  2006-03       Impact factor: 3.891

View more
  87 in total

1.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

2.  HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children.

Authors:  Michael J Boivin; Theodore D Ruel; Hannah E Boal; Paul Bangirana; Huyen Cao; Leigh A Eller; Edwin Charlebois; Diane V Havlir; Moses R Kamya; Jane Achan; Carolyne Akello; Joseph K Wong
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

3.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

Review 4.  HIV-1 tropism.

Authors:  Aikichi Iwamoto; Noriaki Hosoya; Ai Kawana-Tachikawa
Journal:  Protein Cell       Date:  2010-07-07       Impact factor: 14.870

5.  Analysis of HIV tropism in Ugandan infants.

Authors:  Jessica D Church; Wei Huang; Anthony Mwatha; Philippa Musoke; J Brooks Jackson; Danstan Bagenda; Saad B Omer; Deborah Donnell; Clemensia Nakabiito; Chineta Eure; Laura A Guay; Allan Taylor; Paul M Bakaki; Flavia Matovu; Michelle McConnell; Mary Glenn Fowler; Susan H Eshleman
Journal:  Curr HIV Res       Date:  2010-10       Impact factor: 1.581

6.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

7.  Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Authors:  Kathryn M Kitrinos; Heather Amrine-Madsen; David M Irlbeck; J Michael Word; James F Demarest
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

Review 10.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.